Furthermore, studies have indicated that the concurrent administration of CDK7 and CDK12 inhibitors can potently diminish resistance to hedgehog-targeted smoothened inhibitors (SMOi), thereby significantly augmenting the therapeutic efficacy of tumor-targeted therapies [159].These revelations suggest a novel hypothesis: whether super-enhancers could act as regulatory intermediaries in other therapeutic modalities, potentially being utilized as adjutant therapeutic agents within the clinical treatment paradigm. The gene discussed is CDK7; the disease is neoplasm.